203 related articles for article (PubMed ID: 35816666)
1. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
Singh N; Temin S; Baker S; Blanchard E; Brahmer JR; Celano P; Duma N; Ellis PM; Elkins IB; Haddad RY; Hesketh PJ; Jain D; Johnson DH; Leighl NB; Mamdani H; Masters G; Moffitt PR; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Schneider BJ; Spigel DR; Jaiyesimi IA
J Clin Oncol; 2022 Oct; 40(28):3310-3322. PubMed ID: 35816666
[TBL] [Abstract][Full Text] [Related]
2. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G
J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
5. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
6. Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Shimomura Y; Sawa K; Imai T; Ihara Y; Yoshida H; Shintani A
Cancer Sci; 2024 Mar; 115(3):926-936. PubMed ID: 38148717
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
[TBL] [Abstract][Full Text] [Related]
9. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
Jiang J; Zhao C; Zhang F; Liu Z; Zhou K; Ren X; Wan Y
BMJ Open; 2022 Sep; 12(9):e060782. PubMed ID: 36123063
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
11. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
12. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
13. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Singh N; Temin S; Baker S; Blanchard E; Brahmer JR; Celano P; Duma N; Ellis PM; Elkins IB; Haddad RY; Hesketh PJ; Jain D; Johnson DH; Leighl NB; Mamdani H; Masters G; Moffitt PR; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Schneider BJ; Spigel DR; Jaiyesimi IA
J Clin Oncol; 2022 Oct; 40(28):3323-3343. PubMed ID: 35816668
[TBL] [Abstract][Full Text] [Related]
14. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
17. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
18. Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.
Kobayashi T; Kanda S; Fukushima T; Noguchi T; Sekiguchi N; Koizumi T
Thorac Cancer; 2021 Aug; 12(16):2275-2278. PubMed ID: 34184417
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparisons of brigatinib and alectinib for front-line
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
[TBL] [Abstract][Full Text] [Related]
20. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
